Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wu, Heshui
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.	Active, not recruiting	3	408	RoW	KN046, placebo	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Advanced Pancreatic Ductal Adenocarcinoma	04/24	08/24
AK104-217, NCT05859750: A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer	Recruiting	2	78	RoW	AK104, Gemcitabine, Nab-Paclitaxel, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate, Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin	Akeso	Pancreatic Cancer	06/25	12/25
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations	Recruiting	1/2	290	RoW	GFH375	Genfleet Therapeutics (Shanghai) Inc.	KRAS G12D Mutations, Advanced Solid Tumors	07/28	12/28
NCT05911217: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer	Recruiting	1	20	RoW	CT041 autologous CAR T-cell injection, Single Group Assignment	CARsgen Therapeutics Co., Ltd., Fudan University	Pancreatic Cancer	12/26	12/26